Wire · regulatory
US targets Chinese biotech investment, but licensing deals remain exempt
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 24 October 2026 · Fusion42 review
The US government has added biotechnology to its list of sensitive technologies under the COINS Act, allowing it to restrict American investment in Chinese biotech firms developing advanced drugs, though traditional licensing deals remain exempt.
This Wire brief sits within Fusion42's coverage of Biotech, and 5 sources have reported it between 23 Oct 2026 and 3 Nov 2026.
◆ ◆ The Wire takeaway
You face tighter US barriers investing directly in Chinese biotech firms developing advanced drugs but can still pursue growth via licensing deals. Adjust your deal structures this quarter to avoid blocked equity investments and focus on exempt licensing arrangements with China.
◆ Coverage
5 sources · first reported 23 Oct 2026 · latest 3 Nov 2026
◆ Related on Wire
◆ Topics